Home » TapImmune Announces Agreement With AppTec FDA Registered Facility to Begin Testing on Company’s Novel Cancer Vaccine
TapImmune Announces Agreement With AppTec FDA Registered Facility to Begin Testing on Company’s Novel Cancer Vaccine
TapImmune a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced a contractual agreement with AppTec, headquartered in St. Paul, Minnesota, for the preclinical testing of its lead product.
TapImmune
Upcoming Events
-
07May
-
14May
-
30May